Patents by Inventor Kennan C. Marsh
Kennan C. Marsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10238677Abstract: The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.Type: GrantFiled: January 8, 2016Date of Patent: March 26, 2019Assignees: LIVERPOOL SCHOOL OF TROPICAL MEDICINE, ABBVIE INC.Inventors: Thomas W. Von Geldern, Dale J. Kempf, Kennan C. Marsh, Mark John Taylor, Stephen Andrew Ward, Louise Ford, Joseph Turner
-
Patent number: 10072040Abstract: The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.Type: GrantFiled: March 10, 2015Date of Patent: September 11, 2018Assignee: ABBVIE INC.Inventors: Thomas W. von Geldern, Dale J. Kempf, Kennan C. Marsh
-
Publication number: 20170368088Abstract: The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.Type: ApplicationFiled: January 8, 2016Publication date: December 28, 2017Applicants: AbbVie Inc., Liverpool School of Tropical MedicineInventors: Thomas W. VON GELDERN, Dale J. KEMPF, Kennan C. MARSH, Mark John TAYLOR, Stephen Andrew WARD, Louis FORD, Joseph TURNER
-
Publication number: 20160200757Abstract: The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.Type: ApplicationFiled: March 9, 2016Publication date: July 14, 2016Inventors: Thomas W. von Geldern, Dale J. Kempf, Kennan C. Marsh
-
Publication number: 20150259374Abstract: The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.Type: ApplicationFiled: March 10, 2015Publication date: September 17, 2015Inventors: Thomas W. von Geldern, Dale J. Kempf, Kennan C. Marsh
-
Patent number: 8901157Abstract: The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof.Type: GrantFiled: December 2, 2010Date of Patent: December 2, 2014Assignee: AbbVie Inc.Inventors: Dale J. Kempf, Kennan C. Marsh
-
Patent number: 8895051Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.Type: GrantFiled: May 10, 2013Date of Patent: November 25, 2014Inventors: Laman Alani, Donald P. Gauwitz, Dilip Kaul, John M. Lipari, Soumojeet Ghosh, Kennan C. Marsh, Richard H. Whelan, Vanik D. Petrossian
-
Publication number: 20130252985Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.Type: ApplicationFiled: May 10, 2013Publication date: September 26, 2013Inventors: Laman Alani, Donald P. Gauwitz, Dilip Kaul, John M. Lipari, Soumojeet Ghosh, Kennan C. Marsh
-
Patent number: 8501219Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.Type: GrantFiled: January 14, 2010Date of Patent: August 6, 2013Assignee: AbbVie Inc.Inventors: Laman Alani, Donald P. Gauwitz, Dilip Kaul, John M. Lipari, Soumojeet Ghosh, Kennan C. Marsh, Richard H. Whelan, Vanik D. Petrossian
-
Publication number: 20120277190Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.Type: ApplicationFiled: July 9, 2012Publication date: November 1, 2012Inventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Kennan C. Marsh, Robert G. Schmidt, JR., Chih-Hung Lee, Weili Wang, Jerome F. Daanen, Brian S. Brown
-
Patent number: 8232309Abstract: Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.Type: GrantFiled: October 27, 2006Date of Patent: July 31, 2012Assignee: Abbott LaboratoriesInventors: Arthur R. Gomtsyan, Erol K. Bayburt, John R. Koenig, Kennan C. Marsh, Robert G. Schmidt, Jr., Chih-Hung Lee, Weili Wang, Jerome F. Daanen, Brian S. Brown
-
Publication number: 20120178808Abstract: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.Type: ApplicationFiled: March 15, 2012Publication date: July 12, 2012Inventors: Joerg Rosenberg, Matthias Degenhardt, Joerg Breitenbach, Tom L. Reiland, Kennan C. Marsh
-
Publication number: 20120046360Abstract: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.Type: ApplicationFiled: August 24, 2011Publication date: February 23, 2012Inventors: Joerg Rosenberg, Matthias Degenhardt, Jorg Breitenbach, Tom L. Reiland, Kennan C. Marsh
-
Patent number: 8026240Abstract: The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prodrugs of CNS-active compounds, compositions comprising such compounds, methods for making the compounds, salts, and polymorphs, and methods of treating conditions and disorders using such compounds and compositions. Octahydro-pyrrolo[3,4-b]pyrrole N-oxides of formula (I) are prodrugs of histamine-3 antagonists, and are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole N-oxide compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.Type: GrantFiled: September 11, 2008Date of Patent: September 27, 2011Assignee: Abbott LaboratoriesInventors: Marlon D. Cowart, Kennan C. Marsh, Huaqing Liu, Jae Y. Lee, Maria G. Beconi, Jill M. Wetter, Lawrence A. Black, Thomas C. Custer
-
Publication number: 20110091423Abstract: The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof.Type: ApplicationFiled: December 2, 2010Publication date: April 21, 2011Applicant: Abbott LaboratoriesInventors: Dale J. Kempf, Kennan C. Marsh
-
Publication number: 20100323020Abstract: A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bc1-2 family protein inhibitory compound such as ABT-263, having a D90 particle size not greater than about 3 ?m; wherein the aqueous medium further comprises at least one pharmaceutically acceptable surfactant and at least one pharmaceutically acceptable basifying agent such as sodium bicarbonate in amounts that are effective together to inhibit particle size increase. The composition is suitable for oral or parenteral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bc1-2 family proteins, for example cancer.Type: ApplicationFiled: June 17, 2010Publication date: December 23, 2010Applicant: ABBOTT LABORATORIESInventors: Rajeev Gokhale, Kennan C. Marsh, Yi Shi
-
Publication number: 20100280055Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.Type: ApplicationFiled: January 14, 2010Publication date: November 4, 2010Applicant: ABBOTT LABORATORIESInventors: Laman Alani, Donald P. Gauwitz, Dilip Kaul, John M. Lipari, Soumojeet Ghosh, Kennan C. Marsh, Richard H. Whelan, Vanik D. Petrossian
-
Publication number: 20100081715Abstract: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof a other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically ceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.Type: ApplicationFiled: August 30, 2009Publication date: April 1, 2010Inventors: Joerg Rosenberg, Matthias Degenhardt, Joerg Breitenbach, Tom L. Reiland, Kennan C. Marsh
-
Publication number: 20090105267Abstract: The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prodrugs of CNS-active compounds, compositions comprising such compounds, methods for making the compounds, salts, and polymorphs, and methods of treating conditions and disorders using such compounds and compositions. Octahydro-pyrrolo[3,4-b]pyrrole N-oxides of formula (I) are prodrugs of histamine-3 antagonists, and are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole N-oxide compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.Type: ApplicationFiled: September 11, 2008Publication date: April 23, 2009Applicant: Abbott LaboratoriesInventors: Marlon D. Cowart, Kennan C. Marsh, Huaqing Liu, Jae Y. Lee, Maria G. Beconi, Jill M. Wetter, Lawrence A. Black, Thomas C. Custer
-
Patent number: 6911214Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.Type: GrantFiled: September 4, 2001Date of Patent: June 28, 2005Assignee: Abbott LaboratoriesInventors: Laman Alani, Donald P. Gauwitz, Dilip Kaul, John M. Lipari, Soumojeet Ghosh, Kennan C. Marsh, Richard H. Whelan, Vanik D. Petrossian